Figure 7.

Disease progression and survival analyses of melanoma patients under immunotherapy with respect to intracranial PD-L1 expression. Patients were divided into two groups, “high” and “low” PD-L1 expression due to the median PD-L1 expression level. (A) Progression-free survival. Long-rank test statistics show no differences in the progression-free survival for patients with high and low PD-L1 expression (Log-rank p-value 0.160). (B) Overall survival. According to the Kaplan–Meier curve patients with high PD-L1 had a greater benefit from immunotherapy and showed a better overall survival (Log-rank p-value 0.033). Dotted lines indicate the 50% survival probabilities for both groups.